



1647

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Pang et al.

Serial No: 09/634,363

Filed: August 9, 2000

For: Methods and Reagents for Treating
Glucose Metabolic Disorders

Attorney Docket No. CIBT-P02-058

Art Unit: 1647

Examiner: R. DeBerry

RECEIVED

NOV 27 2002

TECH CENTER 1600/290


14/B
M.G.
1/15/23

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents Washington, D.C. 20231 on the date indicated below:

November 18, 2002

Date of Signature
and of Mail Deposit


Brent LaBarge

Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO OFFICE COMMUNICATION

Sir:

In response to the Office Communication, which was mailed from the U.S. Patent and Trademark Office on October 16, 2002, Applicants respectfully request the following amendments be entered into the specification to correct SEQ ID NO. inconsistencies noted during preparation of the sequence listing for the above-referenced patent application:

IN THE SPECIFICATION:

➤ On Page 22, please replace the paragraph at lines 17-20 with the following text:

β¹

PYY is the predominant hormone of the pancreatic polypeptide family in developing mouse and rat pancreas. It is a member of the PP family of proteins, which also includes